A Reinforcement Approach to Improve Diabetes Management



Status:Active, not recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:12 - 21
Updated:1/27/2019
Start Date:July 2014
End Date:November 2019

Use our guide to learn which trials are right for you!

A Reinforcement Approach to Improve Diabetes Management - Randomized Trial

The purpose of this project is to evaluate the efficacy of a behavioral economic intervention
to improve self monitoring of blood glucose (SMBG) in adolescents and young adults with T1D.
The intervention will reinforce patients for conducting SMBG, with escalating reinforcers
provided when patients achieved sustained periods of testing at least 4 times/day at
appropriate intervals. A 6-month trial will be conducted in which 60 patients will be
randomized to: (1) standard care or (2) standard care plus the reinforcement intervention.


Inclusion Criteria:

1. age 12-21 years old;

2. diagnosis of type 1 diabetes (T1D) >12 months via ADA guidelines

3. receiving diabetes treatment at Yale Pediatric Diabetes Clinic and not meeting
clinical care guidelines

4. SMBG user with clinical recommendations to test >4 times/day and using a device that
allows for remote uploading (e.g., Aviva, Contour, Freestyle, Lifescan, etc.;
equipment for uploading will be provided);

5. access to a computer with internet for uploading and sending SMBG data;

6. access to a cell phone with text messaging capabilities and willing to text after SMBG
testing and receive messages about reinforcement;

7. English speaking, able to read at >5th grade level, and pass an informed consent quiz;
and adequate knowledge of insulin dosing and dietary recommendations for managing T1D.

Exclusion Criteria:

1. have a major psychiatric or neurocognitive disorder (e.g., severe learning impairment)
that would inhibit participation;

2. have a major visual impairment;

3. have a significant other medical condition that impacts diabetes management (e.g.,
asthma, rheumatoid arthritis, or other condition that requires steroid treatment);

4. plan to switch insulin delivery mode (injection to pump or vice versa) in the next 12
months, or have recently switched;

5. are participating in another clinical trial.
We found this trial at
1
site
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: William Tamborlane, MD
Phone: 203-737-6877
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials